You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Xenon xe-129 hyperpolarized - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for xenon xe-129 hyperpolarized and what is the scope of freedom to operate?

Xenon xe-129 hyperpolarized is the generic ingredient in one branded drug marketed by Polarean and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Xenon xe-129 hyperpolarized has six patent family members in six countries.

One supplier is listed for this compound.

Summary for xenon xe-129 hyperpolarized
International Patents:6
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 102
DailyMed Link:xenon xe-129 hyperpolarized at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for xenon xe-129 hyperpolarized
Generic Entry Date for xenon xe-129 hyperpolarized*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
GAS;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for xenon xe-129 hyperpolarized

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
American Heart AssociationPhase 2
National Institute for Biomedical Imaging and Bioengineering (NIBIB)Phase 1
General ElectricPhase 1

See all xenon xe-129 hyperpolarized clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for xenon xe-129 hyperpolarized

US Patents and Regulatory Information for xenon xe-129 hyperpolarized

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Polarean XENOVIEW xenon xe-129 hyperpolarized GAS;INHALATION 214375-001 Dec 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Polarean XENOVIEW xenon xe-129 hyperpolarized GAS;INHALATION 214375-001 Dec 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Polarean XENOVIEW xenon xe-129 hyperpolarized GAS;INHALATION 214375-001 Dec 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for xenon xe-129 hyperpolarized

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2015127208 ⤷  Sign Up
Canada 2940109 SYSTEMES DE PRODUCTION DE GAZ NOBLES HYPERPOLARISES AVEC ELIMINATION, DETECTION ET/OU FILTRATION DE NANOAGREGATS ET PROCEDES ET DISPOSITIFS ASSOCIES (HYPERPOLARIZED NOBLE GAS PRODUCTION SYSTEMS WITH NANOCLUSTER SUPPRESSION, DETECTION AND/OR FILTERING AND RELATED METHODS AND DEVICES) ⤷  Sign Up
Hungary E045999 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.